Key Drivers
- Strong liquidity
- High gross margin
- Operating losses
AIAI Summary
SIBN has shifted from a cash‑burn, growth-at-all-costs story to early-stage profitable commercialization—evidenced by 20% revenue growth, ~78–80% gross margins, adjusted EBITDA positivity and initial positive quarterly free cash flow—making execution/timing of product launches, reimbursement rollouts and sustained Opex control the primary value drivers. The biggest actionable opportunity is accelerating outpatient migration via NTAP/reimbursement tailwinds, while the key risk is that any FDA/launch delays or failure to keep Opex in check would quickly reverse margin gains and force dilution.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •High gross margin
- •Operating losses
SIBN has strong liquidity and very high gross margins but is burdened by large operating losses, a sizable accumulated deficit and negative FY cash flow despite recent quarter-level improvement.
Price Behavior
Key Price Behavior Insights:
- •Rapid decline
- •Support test
- •Resistance cluster
Price fell ~17% from $15.48 to $12.79 over the last month, indicating a short-term downtrend with nearest support around $12.77–$12.85 and resistance $15.00–$16.30, so downside remains favored unless price sustains a move back above ~$15.00.
Steep ~17% drop from $15.48 to $12.79 over the last month, raising near-term downside risk
Sentiment & News
Key News Insights:
- •20% revenue growth
- •Positive adjusted EBITDA
- •Q4 free cash flow
SI-BONE delivered record FY25 results with 20% revenue growth, positive adjusted EBITDA, a narrower Q4 GAAP loss, and Q4 free cash flow while issuing 2026 guidance.
The results and cash generation should bolster investor confidence and support valuation improvement ahead of 2026 guidance
Similar Companies in Healthcare
Other companies in the same sector with AI ratings